Adaptive Biotechnologies Corporation

MUN:1HM Stock Report

Market Cap: €664.7m

Adaptive Biotechnologies Management

Management criteria checks 2/4

Adaptive Biotechnologies' CEO is Chad Robins, appointed in Sep 2009, has a tenure of 15.17 years. total yearly compensation is $8.90M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 1.23% of the company’s shares, worth €8.18M. The average tenure of the management team and the board of directors is 6.2 years and 8.8 years respectively.

Key information

Chad Robins

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage7.4%
CEO tenure15.2yrs
CEO ownership1.2%
Management average tenure6.2yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chad Robins's remuneration changed compared to Adaptive Biotechnologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$195m

Jun 30 2024n/an/a

-US$213m

Mar 31 2024n/an/a

-US$215m

Dec 31 2023US$9mUS$663k

-US$225m

Sep 30 2023n/an/a

-US$196m

Jun 30 2023n/an/a

-US$191m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$9mUS$658k

-US$200m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$229m

Dec 31 2021US$9mUS$639k

-US$207m

Sep 30 2021n/an/a

-US$190m

Jun 30 2021n/an/a

-US$171m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$597k

-US$146m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$3mUS$493k

-US$70m

Sep 30 2019n/an/a

-US$62m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$423k

-US$46m

Compensation vs Market: Chad's total compensation ($USD8.90M) is above average for companies of similar size in the German market ($USD1.46M).

Compensation vs Earnings: Chad's compensation has increased whilst the company is unprofitable.

CEO

Chad Robins (50 yo)

15.2yrs

Tenure

US$8,904,267

Compensation

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...

Leadership Team

NamePositionTenureCompensationOwnership
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
€ 8.2m
Julie Rubinstein
President & COO6.8yrsUS$2.97m0.32%
€ 2.1m
Harlan Robins
Co-Founder & Chief Scientific Officer15.2yrsUS$8.61m0.69%
€ 4.6m
Sharon Benzeno
Chief Commercial Officer of Immune Medicine6.8yrsUS$2.88m0.22%
€ 1.5m
Christopher Carlson
Founderno datano datano data
Kyle Piskel
VP, CFO & Principal Accounting Officer3.1yrsUS$1.66m0.10%
€ 695.0k
Karina Calzadilla
Vice President of Investor Relationsno datano datano data
Francis Lo
Chief People Officer5.6yrsno data0.17%
€ 1.2m
Susan Bobulsky
Chief Commercial Officer of MRD4.3yrsno data0.17%
€ 1.1m
Mary Lancelotta
Senior Vice President of MRD BioPharma1.2yrsno datano data

6.2yrs

Average Tenure

50yo

Average Age

Experienced Management: 1HM's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
€ 8.2m
Peter Neupert
Lead Independent Director10.9yrsUS$355.00k0.093%
€ 621.4k
H. Parker
Member of Corporate Advisory Boardno datano datano data
Michelle Griffin
Independent Director5.7yrsUS$330.00k0.035%
€ 234.0k
Robert Hershberg
Independent Director11.8yrsUS$325.00k0.051%
€ 342.2k
Michael Pellini
Independent Director6.8yrsUS$310.00k0.037%
€ 244.5k
Carol Gallagher
Member of Corporate Advisory Boardno datano datano data
Craig Weissman
Member of Corporate Advisory Boardno datano datano data
Graham Allen
Member of Corporate Advisory Boardno datano datano data
Matthew Kahn
Member of Corporate Advisory Boardno datano datano data
Katey Owen
Independent Director3.7yrsUS$310.00k0.038%
€ 252.8k

8.8yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 1HM's board of directors are considered experienced (8.8 years average tenure).